Improvement in Pain Severity Category in Clinical Trials of Pregabalin

Overview

Journal J Pain Res

Publisher Dove Medical Press

Date 2016 Oct 28

PMID 27785092

Citations 5

Authors

Bruce Parsons

Charles E Argoff

Andrew Clair

Birol Emir

Affiliations

Soon will be listed here.

Abstract

Background: Pregabalin is approved by the US Food and Drug Administration for the treatment of fibromyalgia (FM), diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN), and neuropathic pain due to spinal cord injury (SCI). Approval was based on clinical trial data demonstrating statistically significant differences in pain scores versus placebo. However, statistically significant pain relief may not always equate to clinically meaningful pain relief. To further characterize the clinical benefit of pregabalin, this analysis examined shifts in pain severity categories in patients with FM, DPN/PHN (pooled in this analysis), and SCI treated with pregabalin.

Methods: Data were pooled from 23 placebo-controlled trials in patients with FM (1,623 treated with pregabalin, 937 placebo), DPN/PHN (2,867 pregabalin, 1,532 placebo), or SCI (181 pregabalin, 175 placebo). Pain scores were assessed on an 11-point numeric rating scale and categorized as mild (0 to <4), moderate (4 to <7), or severe (7 to 10). Only patients with mean score ≥4 at baseline were randomized to treatment. The percentage of patients shifting pain category from baseline to endpoint for pregabalin and placebo was analyzed using a modified ridit transformation with the Cochran-Mantel-Haenszel procedure.

Results: A higher proportion of patients shifted to a less severe pain category at endpoint with pregabalin compared with placebo. With flexible-dose pregabalin, the percentage of patients improving from: severe to mild (pregabalin versus placebo) was 15.8 versus 13.4 in FM patients, 36.0 versus 16.6 in DPN/PHN patients, 14.3 versus 7.7 in SCI patients; severe to moderate was 28.7 versus 28.2 in FM patients, 32.5 versus 28.2 in DPN/PHN patients, 35.7 versus 28.2 in SCI patients; and moderate to mild was 38.3 versus 26.4 in FM patients, 59.5 versus 41.4 in DPN/PHN patients, 38.6 versus 27.2 in SCI patients.

Conclusion: Compared with placebo, pregabalin is more often associated with clinically meaningful improvements in pain category in patients with FM, DPN, PHN, or SCI.

Citing Articles

Parkinson's Disease: Current Treatment Modalities and Emerging Therapies.

Alotaibi S, Alfayez L, Alkhudhair M Cureus. 2025; 16(12):e75647.

PMID: 39803037 PMC: 11725288. DOI: 10.7759/cureus.75647.

Efficacy of Dorsal Root Ganglion Pulsed Radiofrequency Combined with Paravertebral Injection of Recombinant Human Interferon-α2b in Herpetic Neuralgia.

Fei Y, Huang B, Deng J, Xu L, Yao M J Pain Res. 2021; 14:711-719.

PMID: 33732017 PMC: 7959205. DOI: 10.2147/JPR.S290852.

Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial.

Joharchi K, Memari M, Azargashb E, Saadat N J Diabetes Metab Disord. 2020; 18(2):575-582.

PMID: 31890684 PMC: 6915178. DOI: 10.1007/s40200-019-00427-w.

Therapies for Restless Legs in Parkinson's Disease.

Cochen De Cock V Curr Treat Options Neurol. 2019; 21(11):56.

PMID: 31707535 DOI: 10.1007/s11940-019-0596-8.

A pilot study investigating whether quantitative sensory testing alters after treatment in patients with fibromyalgia.

Wodehouse T, Poply K, Ramaswamy S, Snidvongs S, Bourke J, Tahir H Br J Pain. 2018; 12(4):250-256.

PMID: 30349699 PMC: 6194975. DOI: 10.1177/2049463718776336.

References

Burckhardt C, Clark S, Bennett R . The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991; 18(5):728-33. View

Doth A, Hansson P, Jensen M, Taylor R . The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain. 2010; 149(2):338-344. DOI: 10.1016/j.pain.2010.02.034. View

Bennett R, Bushmakin A, Cappelleri J, Zlateva G, Sadosky A . Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol. 2009; 36(6):1304-11. DOI: 10.3899/jrheum.081090. View

Sharma U, Griesing T, Emir B, Young Jr J . Time to onset of neuropathic pain reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia. Am J Ther. 2010; 17(6):577-85. DOI: 10.1097/MJT.0b013e3181d5e4f3. View

Tolle T, Freynhagen R, Versavel M, Trostmann U, Young Jr J . Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2007; 12(2):203-13. DOI: 10.1016/j.ejpain.2007.05.003. View

Hanley M, Masedo A, Jensen M, Cardenas D, Turner J . Pain interference in persons with spinal cord injury: classification of mild, moderate, and severe pain. J Pain. 2006; 7(2):129-33. DOI: 10.1016/j.jpain.2005.09.011. View

Cardenas D, Nieshoff E, Suda K, Goto S, Sanin L, Kaneko T . A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology. 2013; 80(6):533-9. PMC: 3589291. DOI: 10.1212/WNL.0b013e318281546b. View

Serlin R, Mendoza T, Nakamura Y, Edwards K, Cleeland C . When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995; 61(2):277-284. DOI: 10.1016/0304-3959(94)00178-H. View

Siddall P, Cousins M, Otte A, Griesing T, Chambers R, Murphy T . Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology. 2006; 67(10):1792-800. DOI: 10.1212/01.wnl.0000244422.45278.ff. View

10.

Arezzo J, Rosenstock J, Lamoreaux L, Pauer L . Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008; 8:33. PMC: 2565674. DOI: 10.1186/1471-2377-8-33. View

11.

Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M . Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005; 115(3):254-263. DOI: 10.1016/j.pain.2005.02.032. View

12.

Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K . A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther. 2012; 14(5):R217. PMC: 3580529. DOI: 10.1186/ar4056. View

13.

Arnold L, Crofford L, Mease P, Burgess S, Palmer S, Abetz L . Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008; 73(1):114-20. PMC: 2564867. DOI: 10.1016/j.pec.2008.06.005. View

14.

Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G . An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011; 38(12):2643-52. DOI: 10.3899/jrheum.110569. View

15.

Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T . Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2010; 28(1):109-16. DOI: 10.1111/j.1464-5491.2010.03152.x. View

16.

Stacey B, Barrett J, Whalen E, Phillips K, Rowbotham M . Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain. 2008; 9(11):1006-17. DOI: 10.1016/j.jpain.2008.05.014. View

17.

Zelman D, Dukes E, Brandenburg N, Bostrom A, Gore M . Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain. 2005; 115(1-2):29-36. DOI: 10.1016/j.pain.2005.01.028. View

18.

Freynhagen R, Serpell M, Emir B, Whalen E, Parsons B, Clair A . A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract. 2013; 15(1):47-57. PMC: 4320770. DOI: 10.1111/papr.12146. View

19.

Sabatowski R, Galvez R, Cherry D, Jacquot F, Vincent E, Maisonobe P . Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004; 109(1-2):26-35. DOI: 10.1016/j.pain.2004.01.001. View

20.

Dworkin R, Corbin A, YOUNG Jr J, Sharma U, LaMoreaux L, Bockbrader H . Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003; 60(8):1274-83. DOI: 10.1212/01.wnl.0000055433.55136.55. View